Longview Partners Guernsey LTD Has $454.90 Million Holdings in Thermo Fisher Scientific Inc. $TMO

Key Points

• Longview Partners Guernsey LTD has sold 56,619 shares of Thermo Fisher Scientific Inc., reducing its stake by 5.8%, leaving them with 914,185 shares valued at approximately $454.9 million.
• Several institutional investors increased their holdings in Thermo Fisher, with Vanguard Group Inc. and Northern Trust Corp. among the notable ones expanding their positions by 0.7% and 13.2%, respectively.
• Thermo Fisher Scientific reported revenue of $10.86 billion for the last quarter, surpassing expectations and indicating a 2.9% year-over-year growth in revenue.

Longview Partners Guernsey LTD lowered its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 5.8% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 914,185 shares of the medical research company's stock after selling 56,619 shares during the period. Thermo Fisher Scientific comprises about 3.7% of Longview Partners Guernsey LTD's investment portfolio, making the stock its 18th biggest holding. Longview Partners Guernsey LTD owned 0.24% of Thermo Fisher Scientific worth $454,898,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also modified their holdings of the company. Bernard Wealth Management Corp. acquired a new position in shares of Thermo Fisher Scientific in the fourth quarter worth $25,000. Ameriflex Group Inc. acquired a new position in shares of Thermo Fisher Scientific in the fourth quarter worth $30,000. Keystone Global Partners LLC acquired a new position in shares of Thermo Fisher Scientific in the first quarter worth $31,000. IMA Advisory Services Inc. acquired a new position in shares of Thermo Fisher Scientific in the first quarter worth $35,000. Finally, Navigoe LLC acquired a new position in shares of Thermo Fisher Scientific in the fourth quarter worth $37,000. 89.23% of the stock is owned by institutional investors and hedge funds.

Thermo Fisher Scientific Stock Performance

Shares of NYSE:TMO traded up $2.48 on Thursday, hitting $490.60. 1,407,667 shares of the company were exchanged, compared to its average volume of 2,011,074. The company's 50 day moving average price is $450.59 and its two-hundred day moving average price is $455.26. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $627.88. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. The firm has a market capitalization of $185.25 billion, a price-to-earnings ratio of 28.37, a PEG ratio of 2.61 and a beta of 0.74.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The company had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. During the same quarter in the previous year, the firm posted $5.37 EPS. The business's revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be issued a dividend of $0.43 per share. The ex-dividend date is Monday, September 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.4%. Thermo Fisher Scientific's payout ratio is presently 9.95%.

Insider Activity

In other news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the sale, the chief executive officer directly owned 115,174 shares in the company, valued at approximately $57,697,567.04. The trade was a 7.99% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the sale, the executive vice president owned 22,367 shares in the company, valued at approximately $10,735,712.66. This trade represents a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 28,896 shares of company stock worth $13,603,438. Insiders own 0.33% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on TMO. Wells Fargo & Company cut their price target on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating on the stock in a report on Thursday, July 24th. UBS Group raised their price target on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a "neutral" rating in a report on Thursday, July 24th. Raymond James Financial restated an "outperform" rating and set a $535.00 price target (up previously from $525.00) on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Hsbc Global Res downgraded shares of Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 24th. Finally, HSBC restated a "hold" rating and set a $510.00 price target on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Sixteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $593.00.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.